ORIGINAL RESEARCH article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1627653
Improvement of Revised International Staging System Risk Stratification in Patients with Newly Diagnosed Multiple Myeloma Using a High Bone Marrow Plasma Cell Percentage: A Real-World Study in China
Provisionally accepted
- 1Henan University People’s Hospital, Zhengzhou, China
- 2Henan Provincial People's Hospital, Zhengzhou, China
- 3Zhengzhou University People’s Hospital, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Multiple myeloma (MM) is a heterogeneous malignant plasma cell neoplasm. A significant increase in the bone marrow plasma cell percentage (BMPC%) may adversely affect prognosis. However, a high BMPC% has not been clearly defined. The Revised International Staging System (R-ISS) is considered the standard risk stratification model for newly diagnosed MM (NDMM) and is widely used to assess prognosis. However, a significant proportion of patients were categorized as R-ISS stage II due to high heterogeneity within the population, complicating the accurate prediction of prognosis. This study included 208 patients who were diagnosed with NDMM and received standardized treatment between January 2018 and May 2023, and were categorized into low, medium, and high BMPC% groups. The Kaplan-Meier method was utilized to estimate the progression-free survival (PFS) and overall survival (OS). The Cox proportional hazards model was used to estimate the relationship between BMPC% and survival in patients with R-ISS stage II. The results indicated that a high BMPC% significantly negatively affected OS (hazard ratio [HR] = 4.13, p = 0.002), indicating an adverse prognostic factor. Compared with the low and intermediate BMPC% groups, the high BMPC% group exhibited the shortest median survival time (p < 0.001). Additionally, we analyzed the effect of BMPC% on survival rates stratified by R-ISS stage. Within the stage II subgroup, the OS for the BMPC% stratified groups were NA, 50.1 months, and 29.6 months (p = 0.01). We used external validation to confirm the reliability of the results. The results also indicated that a high BMPC% significantly negatively affected OS (p < 0.001). This study demonstrated that including a BMPC% ≥50% can enhance the predictive value of the R-ISS for NDMM, particularly in patients with R-ISS stage II.
Keywords: R-ISS, BMPC%, prognosis, NDMM, Real word study
Received: 13 May 2025; Accepted: 17 Sep 2025.
Copyright: © 2025 Sun, Song, Wang, Zhang, Shi and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jie Shi, jieshicn@outlook.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.